OncLive® On Air

Dr Borgen recaps a presentation he made at the 2022 Miami Breast Cancer Conference highlighting the flaws with preprints, outlining his recommendations for fixing peer review, and explaining how this affects cancer research. 

Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effects clinicians should be aware of when prescribing the doublet, and the potential next steps for this therapy in melanoma.

Dr. Elias Jabbour, a leading oncologist from MD Anderson Cancer Center, dives deep into chronic myeloid leukemia (CML) advancements. He reveals exciting findings from the ASCEMBL trial showing asciminib's higher efficacy compared to bosutinib. Jabbour discusses ponatinib's optimized dosing strategy and its effectiveness against specific mutations. He highlights the safety profiles of both drugs, emphasizing considerations for patients at high vascular risk. This insightful talk sheds light on the future of CML treatment decisions.

Dr Bardia discusses data from DESTINY-Breast03 (NCT03529110), HER2CLIMB (NCT02614794), and NALA (NCT01808573), important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.

Dr D’Abreo discusses adverse effects such as fatigue, nausea and vomiting, and interstitial lung disease, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.

Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with breast cancer, and potential avenues for future investigations.

Dr Mesa discusses the data that led to the FDA approval of pacritinib, toxicities clinicians should be aware of when prescribing the JAK inhibitor, and the next steps for pacritinib in the space.

Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an investigation of nivolumab plus ipilimumab for patients with high tumor mutational burden, and more.

Drs Lyle and Patel review some of the challenges associated with the diagnosis and management of myelodysplastic syndromes, the current treatment landscape, and the role of next-generation sequencing and optimal testing practices in the field.

Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.